Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827358 | 1.00 | LGALS8 (0.50) | LGALS8LGALS3SLC6A2BCHESSTR1 | |
| SCHEMBL7460671 | 0.92 | BCHE (0.46) | LGALS8LGALS3SLC6A2BCHESSTR1 | |
| SCHEMBL7152123 | 0.85 | PDPK1 (0.43) | SLC6A2BCHEPDPK1MTORPTPN2 | |
| SCHEMBL3830803 | 0.84 | PDPK1 (0.40) | LGALS8LGALS3SLC6A2BCHESSTR1 | |
| SCHEMBL18825279 | 0.84 | BCHE (0.50) | LGALS8BCHESSTR1SSTR2SSTR4 | |
| SCHEMBL31064991 | 0.84 | BCHE (0.50) | LGALS8BCHESSTR1SSTR2SSTR4 | |
| SCHEMBL18825292 | 0.84 | BCHE (0.50) | LGALS8BCHESSTR1SSTR2SSTR4 | |
| SCHEMBL23343940 | 0.84 | LGALS8 (0.53) | LGALS8LGALS3SLC6A2BCHESSTR1 | |
| SCHEMBL6513954 | 0.83 | LGALS8 (0.43) | LGALS8LGALS3SLC6A2BCHESSTR1 | |
| SCHEMBL22266752 | 0.82 | LGALS8 (0.47) | LGALS8LGALS3SLC6A2BCHESSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353556-A4 | SOLID- AND SOLUTION -PHASE SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS | MASSACHUSETTS INST TECHNOLOGY (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-1809603-A4 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2009-09-02 | — | — | EP | disclosed |
| EP-1809603-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006043839-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-04-27 | — | — | WO | disclosed |
| US-6846917-B2 | Solid- and solution-phase synthesis of heparin and other glycosaminoglycans | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1353556-A2 | SOLID- AND SOLUTION -PHASE SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030013862-A1 | Solid- and solution-phase synthesis of heparin and other glycosaminoglycans | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-16 | — | — | US | disclosed |
| WO-2002058633-A2 | SOLID- AND SOLUTION -PHASE SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013862-A1 | Solid- and solution-phase synthesis of heparin and other glycosaminoglycans | HPSE, TLR3, HDGF | LGALS8 584/4885LGALS3 824/4885SLC6A2 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.